NO20073239L - TNF-antagonister - Google Patents

TNF-antagonister

Info

Publication number
NO20073239L
NO20073239L NO20073239A NO20073239A NO20073239L NO 20073239 L NO20073239 L NO 20073239L NO 20073239 A NO20073239 A NO 20073239A NO 20073239 A NO20073239 A NO 20073239A NO 20073239 L NO20073239 L NO 20073239L
Authority
NO
Norway
Prior art keywords
tnf
polypeptides
treatment
binding
tnf antagonists
Prior art date
Application number
NO20073239A
Other languages
English (en)
Inventor
Thor Las Holtet
Mikkel Holmen Andersen
Mette Munch
Helle Krogh Ottow
Josephus Dirk Nieland
Original Assignee
Anaphore Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaphore Inc filed Critical Anaphore Inc
Publication of NO20073239L publication Critical patent/NO20073239L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Sammendrag TNF-bindende polypeptider basert på humane tetranektin C-type lectinliknende domener (TTLD) med forbedret bindingsegenskaper og forbedret effektivitet. Polypeptidene omfatter et TNF-bindende domene med aminosyresekvensen KRWSRYF (SEQ ID NO: l). Det frembringes også fremgangsmåte for å fremstille polypetiden ifølge oppfinnelsen. Polypeptidene kan anvendes for fremstilling av farmasøytiske sammensetninger, og for behandling av et individ som har en patologi mediert TNF, slik som behandling av reumatoid artritt.
NO20073239A 2004-11-22 2007-06-22 TNF-antagonister NO20073239L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62934304P 2004-11-22 2004-11-22
DKPA200401813 2004-11-22
PCT/DK2005/000742 WO2006053568A1 (en) 2004-11-22 2005-11-21 Tnf antagonists

Publications (1)

Publication Number Publication Date
NO20073239L true NO20073239L (no) 2007-08-17

Family

ID=35840156

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073239A NO20073239L (no) 2004-11-22 2007-06-22 TNF-antagonister

Country Status (10)

Country Link
US (1) US7820622B2 (no)
EP (1) EP1824878A1 (no)
JP (1) JP2008520214A (no)
KR (1) KR20070095296A (no)
AU (1) AU2005306168A1 (no)
BR (1) BRPI0518042A (no)
CA (1) CA2587948A1 (no)
NO (1) NO20073239L (no)
NZ (1) NZ555353A (no)
WO (1) WO2006053568A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ568809A (en) 2005-12-22 2011-08-26 Genentech Inc Recovering and purification of VEGF proteins from prokaryotic cells using polyanionic agents
ZA200900229B (en) 2006-07-14 2010-04-28 Genentech Inc Refolding of recombinant proteins
BRPI0719597A2 (pt) 2006-11-22 2013-12-17 Adnexus A Bristol Myers Squibb R & D Company Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir
EP2072527A1 (en) 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
WO2010042890A2 (en) * 2008-10-10 2010-04-15 Anaphore, Inc. Polypeptides that bind trail-ri and trail-r2
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
CN107969128A (zh) 2015-04-17 2018-04-27 高山免疫科学股份有限公司 具有可调的亲和力的免疫调节蛋白
US11124558B2 (en) * 2017-06-02 2021-09-21 The Feinstein Institutes For Medical Research Use of tetranectin and peptide agonists to treat inflammatory diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9409768D0 (en) 1994-05-16 1994-07-06 Medical Res Council Trimerising polypeptides
ATE282092T1 (de) 1997-06-11 2004-11-15 Borean Pharma As Trimerisierendes modul
WO2002048189A2 (en) 2000-12-13 2002-06-20 Borean Pharma A/S Combinatorial libraries of proteins having the scaffold structure of c-type lectin-like domains
AU2003225416A1 (en) 2002-06-25 2004-01-06 Medical Patents Limited Injection syringe having a retractable injection needle
CA2503697A1 (en) 2002-10-29 2004-05-13 Borean Pharma A/S Trimeric binding proteins for trimeric cytokines

Also Published As

Publication number Publication date
BRPI0518042A (pt) 2008-10-28
WO2006053568A1 (en) 2006-05-26
KR20070095296A (ko) 2007-09-28
NZ555353A (en) 2009-12-24
JP2008520214A (ja) 2008-06-19
EP1824878A1 (en) 2007-08-29
US7820622B2 (en) 2010-10-26
US20090155843A1 (en) 2009-06-18
CA2587948A1 (en) 2006-05-26
AU2005306168A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
NO20073239L (no) TNF-antagonister
JP7128246B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
JP7007333B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
RU2381233C2 (ru) Агонисты рецептора меланокортина
WO2004101611A3 (en) Peptides that bind to the erythropoietin receptor
Carstens et al. Structure–Activity Studies of Cysteine‐Rich α‐Conotoxins that Inhibit High‐Voltage‐Activated Calcium Channels via GABAB Receptor Activation Reveal a Minimal Functional Motif
EA201070623A1 (ru) Конструкция из полипептидов однодоменных антител, применение композиции, ее содержащей, и способ лечения ревматоидного артрита
WO2006052723A3 (en) G protein coupled receptor agonists and antagonists and methods of use
ATE417595T1 (de) Keratin-bindende polypeptide
US20100022446A1 (en) Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
UA105625C2 (uk) Пастка vegf і її терапевтичне застосування
NO20070496L (no) Kimere proteiner og anvendelser derav.
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
JP2010501191A5 (no)
JP2009526756A5 (no)
Garcia‐Redondo et al. Vascular effects of egg white‐derived peptides in resistance arteries from rats. Structure–activity relationships
BRPI0714844B8 (pt) molécula de ácido nucleico e seus usos, composição farmaceutica e complexo
MX2021010404A (es) Anticuerpos que se unen a una forma escindida de calreticulina mutante, y agente de diagnostico, preventivo o terapeutico para las neoplasias mieloproliferativas.
NZ599114A (en) Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
WO2011012609A3 (en) Anti - tgf - beta receptor type ii single domain antibodies
CA2581110A1 (en) Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions
ZA202301784B (en) Crf2 receptor agonists and their use in therapy
WO2003002604A3 (en) G protein coupled receptors and dna sequences thereof
EP2530090A3 (en) Anti-IL-13R alpha 1 antibodies and their uses thereof
EA200801077A1 (ru) Антагонисты взаимодействия pf4 и rantes

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO

FC2A Withdrawal, rejection or dismissal of laid open patent application